Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-087960 · Präparat HOS-083591
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 8101–8723 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088010 · Präparat HOS-083599
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 8099–8721 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-109934 · Präparat HOS-093279
Simvastatin: Co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma
concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34%
and 46%, respectively. The plasma concentrations of bosentan were not affected by concomitant
simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) cholesterol (HOS-087961) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage e61552011a59d82e1160ea4b8f6c7100809ad1f6ecc47f422b7e2435916462b3 · Zeichen 7072–7459 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 32 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-109985 · Präparat HOS-093279
Simvastatin: Co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma
concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34%
and 46%, respectively. The plasma concentrations of bosentan were not affected by concomitant
simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) cholesterol (HOS-087961) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage e61552011a59d82e1160ea4b8f6c7100809ad1f6ecc47f422b7e2435916462b3 · Zeichen 7016–7403 im Abschnitt
Wechselwirkungen · Clopidogrel Zentiva (previously Clopidogrel Winthrop)
Clopidogrel Zentiva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-209903 · Präparat HOS-154399
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-03T16:45:00Z · SHA-256 e0215a720388221c98b7ac2dbc71d7bb651807eaa839c43dbd3c29e450499ab6 · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 7965–8587 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 200 mg tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-120837 · Präparat HOS-095225
6
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage fa6d27cbc82a21288339e4f7f46bb93471086af14bcf8331561e4329f38445f9 · Zeichen 5105–5587 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 400 mg tablets · Abschnitt 4.5 · PDF-Seite 24–25
HOS-120879 · Präparat HOS-095225
Simvastatin
A study in healthy subjects showed an average decrease of 50% in systemic exposure to simvastatin
when co-administered with eslicarbazepine acetate 800 mg once daily, most likely caused by an
induction of CYP3A4. An increase of the simvastatin dose may be required when used concomitantly
with eslicarbazepine acetate.
24
Rosuvastatin
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 06f36e0e97255f9961271f760b71fb84ff4600381544db3887bc1ba99160bf77 · Zeichen 4707–5585 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 600 mg tablets · Abschnitt 4.5 · PDF-Seite 42–43
HOS-120920 · Präparat HOS-095225
42
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage a362260269dab7484f56ceea007d350fe37dda64c9af71e77dc759d69fc2f0e1 · Zeichen 5104–5587 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 800 mg tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-120961 · Präparat HOS-095225
60
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 1486082baf184fe0e5ec3325f2001a0a45d9631cf49edcfa2f2a716df7eb49f3 · Zeichen 5108–5591 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 50 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 78–79
HOS-121003 · Präparat HOS-095225
Rosuvastatin
78
There was an average decrease of 36-39% in systemic exposure in healthy subjects when
co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction
is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in
combination with induction of its metabolism. Since the relationship between exposure and drug
activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage dfa31a4feae66a5364fd92441410bab414eb321ac7cb70650fa0a4489e80ee15 · Zeichen 5040–5587 im Abschnitt
Wechselwirkungen · Clopidogrel Teva (hydrogen sulphate)
Clopidogrel Teva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-210589 · Präparat HOS-154547
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T12:25:00Z · SHA-256 2668df6ec61f9f4f66d3079105d2dc6c533c7c482102d41117d3a9ecab3c3583 · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 7979–8601 im Abschnitt
Wechselwirkungen · Clopidogrel Krka
Clopidogrel Krka 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-210644 · Präparat HOS-154555
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T09:49:00Z · SHA-256 de285f540dd9461c605738f58c4125215a83fbcefb35a3be3d9119eb1b2b68a9 · Passage 7d4f66c1e9e20aaefc05b48193a27de8f32c87b4363f5f9451600341e96458ac · Zeichen 7980–8603 im Abschnitt
Wechselwirkungen · Zyllt
Zyllt 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-121556 · Präparat HOS-095389
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T12:07:00Z · SHA-256 f7bf5ef29f88fd676dd0507812419bb944fe4584c2c7bb6fde3ba14cc8084d6f · Passage 7d4f66c1e9e20aaefc05b48193a27de8f32c87b4363f5f9451600341e96458ac · Zeichen 7978–8601 im Abschnitt
Wechselwirkungen · Grepid
Grepid 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-121598 · Präparat HOS-095397
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-23T11:55:00Z · SHA-256 77bedbd07ba7109037505e509b70d3e89cce68a41661a537751991f1f383eb00 · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 7988–8610 im Abschnitt
Wechselwirkungen · Clopidogrel Taw Pharma (previously Clopidogrel Mylan)
Clopidogrel Taw Pharma 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-212094 · Präparat HOS-154824
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
As with other oral P2Y12 inhibitors, co-administration of opioid agonists has the potential to delay
and reduce the absorption of clopidogrel presumably because of slowed gastric emptying. The clinical
relevance is unknown. Consider the use of a parenteral antiplatelet agent in acute coronary syndrome
patients requiring co-administration of morphine or other opioid agonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) morphine (HOS-086053) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-12-19T13:48:00Z · SHA-256 b3992d2973f4ae730e07521176d9e9c00fa2564f1a5afd425a7a1ce9b1db9a91 · Passage 10e12fe0673d2ce00c9827d0024ebe033e7a54b7b0305a6f2793f04d9e4c5929 · Zeichen 7871–8873 im Abschnitt
Wechselwirkungen · Clopidogrel TAD
Clopidogrel TAD 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-212131 · Präparat HOS-154832
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-13T14:13:00Z · SHA-256 92374ef557d036eb7238428b43050aa768aa319968c19ef57a4d1f13dfef0986 · Passage 7d4f66c1e9e20aaefc05b48193a27de8f32c87b4363f5f9451600341e96458ac · Zeichen 7979–8602 im Abschnitt
Wechselwirkungen · Clopidogrel Krka d.d. (previously Zopya)
Clopidogrel Krka d.d. 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-212171 · Präparat HOS-154840
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-13T12:00:00Z · SHA-256 38319568b52a779a4ed92c9d4481ec0fa339af9002213bb9c72643f9947622a1 · Passage 7d4f66c1e9e20aaefc05b48193a27de8f32c87b4363f5f9451600341e96458ac · Zeichen 7980–8603 im Abschnitt
Wechselwirkungen · Clopidogrel BGR (previously Zylagren)
Clopidogrel BGR 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-212211 · Präparat HOS-154848
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2020-03-11T02:00:00Z · SHA-256 2175bf409580f587aac82c2a36b07767e3fa81e6ce88fcb5b47bd52ea2f3eef2 · Passage 7d4f66c1e9e20aaefc05b48193a27de8f32c87b4363f5f9451600341e96458ac · Zeichen 7405–8028 im Abschnitt
Wechselwirkungen · Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-212263 · Präparat HOS-154856
Other interactions with clopidogrel and ASA
More than 30,000 patients entered into clinical trials with clopidogrel plus ASA at maintenance doses
lower than or equal to 325 mg, and received a variety of concomitant medicinal products including
diuretics, beta blockers, ACE Inhibitors, calcium antagonists, cholesterol lowering agents, coronary
vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists
without evidence of clinically significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2019-11-13T14:36:00Z · SHA-256 fdf7b1939833e55bbc6a1c8732c66c147ac4404b0347a1c2e50406556ee7b8c0 · Passage 0bc46143329993339916e0d90452548723f1a63122812b081daaecbd4d7bf69c · Zeichen 8855–9367 im Abschnitt
Wechselwirkungen · Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Clopidogrel Viatris 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-212542 · Präparat HOS-154922
Apart from the specific medicinal product interaction information described above, interaction studies
with clopidogrel and some medicinal products commonly administered in patients with
atherothrombotic disease have not been performed. However, patients entered into clinical trials with
clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers,
ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents
(including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
significant adverse interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) clopidogrel (HOS-087927) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T14:50:00Z · SHA-256 e9e7d4f8970d3988a1ba7d9aaf346cccae34503164616a23f43de2932801e6e6 · Passage 86bd8e67d4c43d350fd182feee0f04c9624b185ee3fb5f19f3d0defcfe755b19 · Zeichen 7981–8603 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.